



DECEMBER 10–13, 2024

HENRY B. GONZALEZ CONVENTION CENTER • SAN ANTONIO, TX

Program

[Last updated: October 18, 2024]

Tuesday, December 10 (All times are in CST)

- 12:00 – 1:30 pm **Prevention Special Session: Mechanisms of Obesity Related Risk for Breast Cancer and Approaches to Risk Reduction**
Moderator: Carol Fabian, University of Kansas Medical Center, Westwood, Kansas
- Lifestyle, Genetic, and Epigenetic Interactions in Predicting Development of Obesity and Response to Calorie Restriction and Physical Activity
Catherine Duggan, the Fred Hutchinson Cancer Center, Seattle, Washington
 - Achieving Sufficient Fat loss and Metabolic Improvement to Reduce Cancer Risk: Newer Generation GLP-1n and GIP Receptor Agonists (Nutrient Sensing Hormone (NUSH) - Based Therapeutics
Neil Iyengar, Memorial Sloan Kettering Cancer Center
 - Impact and Types of Exercise and Pharmacotherapy in Weight Loss
John Jakicic, University of Kansas Medical Center, Westwood, Kansas
 - **Panel Discussion**
- 12:00 – 1:45 pm **Special Session 3: Sex, Drugs, Rock & Roll**
Moderator: Christine Ambrosone, Roswell Park Comprehensive Cancer Center, Buffalo, New York
Patient Advocate: Tomika Bryant, King of Prussia, Pennsylvania
- Supplements and Cannabis
Heather Greenlee, Fred Hutchinson Cancer Center, Seattle, Washington
 - Sexual Health
Don Dizon, Legorreta Cancer Center at Brown University/Lifespan Cancer Institute, Providence, Rhode Island
 - Exercise During Treatment
Rikki Cannioto, Roswell Park Comprehensive Cancer Center, Buffalo, New York
 - Alcohol
Marilyn Kwan, Kaiser Permanente Northern California, Pleasanton, California
 - **Panel Discussion**
- 12:00 – 1:45 pm **Career Development: Navigating the Road to Success – Early Funding for Research and Beyond**

Moderator: Brenda Ernst, Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona

- Federal Funding Opportunities
Larissa Korde, Johns Hopkins School of Medicine, Washington, D.C.
- Foundation Funding
Sara Tolaney, Dana-Farber Cancer Institute, Boston, Massachusetts
- Interactions with Industry
Minetta Liu, Natera, Austin, Texas
- **Panel Discussion**

2:00 – 3:45 pm

Clinical Workshop: Dose Optimization in Breast Medical Oncology

2:00 – 3:45 pm

Translational Workshop: Cancer Immunology Discovery Approaches into Clinical Trials

Moderator: Christine Desmedt, KU Leuven, Leuven, Belgium

- Multiplex Imaging for Precision Oncology
Raza Ali, Cancer Research UK, Cambridge, United Kingdom
- Single Cell T-Cell Receptors and B-Cell Receptors
Diether Lambrechts, Catholic University of Leuven, Leuven, Belgium
- Spatial Transcriptomics
Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium
- Cancer Immunology Discovery Approaches into Clinical Trials
Emanuela Romano, Institut Curie, Paris, France
- **Panel Discussion**

2:30 – 4:00 pm

Career Development: Clinical Trial/Protocol Development

Moderator: Saranya Chumsri, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida

- Partnerships in clinical research
Edith Perez, Mayo Clinic, Kenwood, California
- Decentralized Clinical trials
Tatiana Prowell, FDA, Silver Spring, Maryland
- Patient-centered Design
Amylou Dueck, Mayo Clinic Cancer Center, Scottsdale, Arizona

4:00 – 5:45 pm

Educational Session 1: Mind the Gap — Breast Cancer in the Young

Moderator: Matteo Lambertini, University of Genova - IRCCS Ospedale Policlinico, San Martino, Genoa, Italy

Patient Advocate: Na'Diah Smith, Dallas, Texas

- Biology of Breast Cancer in Young Women
Camila Dos Santos, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
- Ovarian Suppression: Who, When, Why, and for How Long
Prudence Francis, Peter MacCallum Cancer Centre, Melbourne, Australia
- Survivorship
Jennifer Sheng, Johns Hopkins University, Baltimore, Maryland

- **Panel Discussion**

4:00 – 5:45 pm

Educational Session 2: Liquid Biopsy: MRD, CT DNA, and Monitoring Response to Treatment**Moderator: Adrian Lee**, University of Pittsburgh, Pittsburgh, Pennsylvania

Patient Advocate: Ellen Landsberger, New York City, New York

- Review of Current Technologies
Heather Parsons, Dana-Farber Cancer Institute, Boston, Massachusetts
- Early Detection and Molecular Recurrent Disease
Ben Park, Vanderbilt University Medical Center, Nashville, Tennessee
- Utility in the Metastatic Setting
David Cescon, UHN Princess Margaret Cancer Centre, Toronto, Canada
- **Panel Discussion**

4:00 – 5:45 pm

Educational Session 3: Tumor Heterogeneity and Evolution**Moderator: Reuben S. Harris**, UT Health San Antonio, San Antonio, Texas

- Therapy Induced Evolution
Nicholas Navin, UT MD Anderson Cancer Center, Houston, Texas
- Genomic and Microenvironment Determinants of Breast Cancer Progression
Christina Curtis, Stanford University, Stanford, California
- Single Cell Genomics in Triple Negative Breast Cancer
Ashley Laughney, Weill Cornell Medicine, New York, New York
- **Panel Discussion**

4:00 – 5:45 pm

Educational Session 4: Optimizing Early HER2 Positive Breast Cancer Treatment**Moderator: Javier Cortes**, International Breast Cancer Center, Barcelona, Spain

Patient Advocate: Thelma Brown, Birmingham, Alabama

- Neoadjuvant Management and Adaptive Strategies
Gabe Sonke, Netherlands Cancer Institute, Amsterdam, Netherlands
- Treatment of Small Tumors in Early-Stage Setting
Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts
- Post Neoadjuvant Management for non pCR
Joyce O'Shaughnessy, Baylor University, Dallas, Texas
- **Panel Discussion**

5:45 – 6:15 pm

Refreshment and Networking Break

6:00 – 7:00 pm

Late Breaking Oral Presentations

Wednesday, December 11 (All times are in CST)

- 7:00 – 8:30 am **Concurrent Poster Spotlight Sessions 1-5**
- 8:30 – 8:40 am **Welcome and Opening Remarks**
- 8:40 – 9:20 am **Keynote Address**
Dr. William Kaelin, Dana-Farber Cancer Institute, Boston, Massachusetts
- 9:20 – 11:30 am **General Session 1**
- 11:30 am – 12:00 pm **William L. McGuire Memorial Lecture**
Laura J. van 't Veer, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco
- 12:00 – 12:50 pm **Rapid Fire 1**
- 12:30 – 2:00 pm **Poster Session 1**
Halls 2-3
- 12:00 – 1:45 pm **Early Detection**
Moderator: Ismail Jatoi, UT Health San Antonio Mays Cancer Center, San Antonio, Texas
- Risk-Based Screening in the Average Population
Karla Kerlikowske, University of California San Francisco, San Francisco, California
 - Novel Imaging Modalities
Connie Lehman, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts
 - Screening for High-Risk Women
Speaker to be announced
 - **Panel Discussion**
- 1:00 – 3:30 pm **Navigating Success: Women's Career Development**
- Moderator: Anne Welsh**, Psychologist and Executive Coach, Cambridge, Massachusetts
- Designed for women who have completed their training and are now in practice, this workshop is a dynamic and inclusive event aimed to inspire and support women pursuing careers in scientific research. The workshop provides a platform for accomplished female scientists to share their experiences, provide mentorship, and discuss strategies to overcome gender-related challenges in the field of cancer research. Through engaging talks, interactive sessions, and networking opportunities, participants gain valuable insights, build a stronger support network, and acquire practical tools to thrive and excel in their scientific research careers.

- Setting the stage for Success
Anne Welsh, Psychologist and Executive Coach, Cambridge, Massachusetts
- Evidence-based strategies to address systemic barriers facing women researchers
Reshma Jagsi, Emory University, Atlanta, Georgia

1:00 – 1:50 pm

Clinical Case Discussions**Moderator: Debra Patt**, Texas Oncology, Austin, Texas

Patient Advocate: Kelly Shanahan, Tahoe, California

- **Sonya Reid**, Vanderbilt Ingram Cancer Center, Nashville, Tennessee
- **Icro Meattini**, Florence University Hospital, Florence, Italy
- **Tari King**, Dana-Farber Cancer Institute, Boston, Massachusetts
- **Joannie Ivory**, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
- **Anne Salomon**, Institut Curie, Paris, France
- **Harold Burstein**, Dana-Farber Cancer Institute, Boston, Massachusetts

2:00 – 3:00 pm

State of the Art Session 1: The Winding Road of Immune Biomarkers in Early Breast Cancer**Moderator: Sherene Loi**, Peter MacCallum Cancer Centre, Melbourne, Australia

- TILs: An Update After 10 Years of Research
Roberto Salgado, Peter MacCallum Cancer Centre, Melbourne, Australia
- Immune Biomarkers Beyond TILs
Justin Balko, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
- Deploying Immune Biomarkers in Clinical Trials
Priyanka Sharma, University of Kansas Medical Center, Westwood, Kansas
- **Panel Discussion**

2:00 – 3:00 pm

Clinical Controversies: Omission of Axillary Staging in ER Positive Breast Cancer: Implications on Adjuvant Therapies**Moderator: Monica Morrow**, Memorial Sloan Kettering Cancer Center, New York, New York

- Omission of Axillary Staging in ER+ Disease: What is The Data?
Elizabeth Mittendorf, Dana-Farber Cancer Institute, Boston, Massachusetts
- Omission of Axillary Staging in ER+ Disease: Implications for Radiotherapy
Speaker to be announced
- Omission of Axillary Staging in ER+ Disease: Implications for Adjuvant Systemic Therapy
Kevin Kalinsky, Emory Winship Cancer Institute, Atlanta, Georgia

- Radiation Post pCR
Richard Zellars, Indiana University School of Medicine, Indianapolis, Indiana
- **Panel Discussion**

3:00 – 3:30 pm

AACR Outstanding Investigator Award for Breast Cancer Research

3:30 – 5:15 pm

Educational Session 5: Unlocking New Targets with Molecular Degraders**Moderator: Carlos Arteaga**, UT Southwestern Medical Center, Dallas, Texas

- PROTACs
- Lysosome-targeting Chimeras
- Carolyn Bertozzi, Stanford University, Palo Alto, California
- Biparatropic Antibodies
- **Panel Discussion**

3:30 – 5:15 pm

Educational Session 6: Case Based Clinical Approach to ER Positive Metastatic Breast Cancer**Moderator: Sara Hurvitz**, Fred Hutch Cancer Center, Seattle, Washington

Case Presentations and Discussants:

Michael Oliphant, Harvard Medical School, Boston, Massachusetts**Aditya Bardia**, UCLA David Geffen School of Medicine, Los Angeles, California**Neil Vasan**, Columbia University Irving Medical Center, New York, New York**Dan Stover**, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio**Amy Beumer**, Patient Advocate, Mason, Ohio

- Case 1: New diagnosis ER+HER2-MBC: genomic considerations
- Case 2: Can we delay CDK4/6i treatment until the second line?
- Case 3: Selecting therapy after progression of disease on CDK4/6i therapy in patients with PI3K pathway mutations
- Case 4: Selecting treatment for patient with tumor ESR1 mutation
- Case 5: When it's time to move on from endocrine approaches, chemo or ADC?

3:30 – 5:15 pm

Educational Session 7: People's Choice - Future Directions in Antibody Drug Conjugates

Speakers to be announced

3:30 – 5:15 pm

Educational Session 8: Optimizing Local Therapy**Moderator: Tari King**, Dana-Farber Brigham Cancer Center, Boston, Massachusetts

Patient Advocate: Yvonne Florance, Philadelphia, Pennsylvania

- Let's Talk About PBI
Atif Khan, Memorial Sloan Kettering Cancer Center, New York, New York
- Axillary Management: When to Dissect and When to Radiate
Stephanie Wong, Jewish General Hospital Segal Cancer Centre, McGill University Medical School, Montreal, Canada
- Surgical Prevention and Management of Lymphedema

Sarah McLaughlin, Mayo Clinic, Jacksonville, Florida

- Panel Discussion

5:30 – 7:00 p.m.

Poster Session 2

Halls 2-3

Thursday, December 12 (All times are in CST)

- 7:00 – 8:30 am **Concurrent Poster Spotlight Sessions 6-10**
- 8:30 – 9:00 am **Plenary Lecture**
- The Grand Challenge of Unraveling Social vs Biological Drivers of Racial Disparities in Cancer Outcomes
Melissa B. Davis, Morehouse School of Medicine, Atlanta, Georgia
- 9:00 – 11:45 am **General Session 2**
- 12:30 -2:00 pm **Poster Session 3**
Halls 2-3
- 12:00 – 12:50 pm **Rapid Fire 2**
- 12:30 – 1:45 pm **The Future of Cancer Genetics Is Here**
Moderator: **Claudine Isaaks**, Georgetown University, Washington, DC
Patient Advocate: Tanja Spanic, Europa Donna Slovenia, Ljubljana, Slovenia
- Saturation Genome Editing-Based Functional and Clinical Classification of VUS in BRCA2
Fergus Couch, Mayo Clinic, Rochester, Minnesota
 - Updates on Risk Prediction Models
Antonis Antoniou, Cancer Research UK Cambridge Center, Cambridge, United Kingdom
 - Reversion Mutations in BRCA1/2 in Response to Therapy
Katherine Nathanson, University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania
 - **Panel Discussion**
- 1:00 – 1:50 pm **Molecular Tumor Board**
Moderator: **Phillipe Afthimos**, Insitut Jules Bordet, Brussels, Belgium
- **Dara Aisner**, University of Colorado Medical School, Aurora, Colorado
 - **Jorge Reis-Filho**, AstraZeneca, Gaithersburg, Maryland
 - **Philippe Bedard**, Princess Margaret Cancer Centre, Toronto, Canada
 - **Jenna Canzoniero**, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland
 - **Bob Riter**, Cornell University, Ithaca, New York
- 2:00 – 3:00 pm **Translational Controversies**
Moderator: **Antonio Wolff**, Johns Hopkins University, Baltimore, Maryland
- How to Define Triple Negative Breast Cancer
Rebecca Dent, National Cancer Center Singapore, Singapore
Charles Perou, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
 - Tumor Agnostic Drug Development
Funda Meric, MD Anderson Cancer Center, Houston, Texas
Fabrice Andre, Institut Gustave Roussy, Villejuif, France

- 2:00 – 3:00 pm **State of the Art: Revolutionizing Diagnosis and Discovery with Artificial Intelligence**
 Moderator: **Fred Howard**, University of Chicago, Chicago, Illinois
- Pathology
Speaker to be announced
 - Imaging and Screening
Ritse Mann, Netherlands Cancer Institute, Amsterdam, Netherlands
 - Drug Discovery, Deep Learning, and Large Data Management
Speaker to be announced
 - **Panel Discussion**
- 3:00 – 3:30 pm **AACR Distinguished Lecture in Breast Cancer Research**
- 3:30 – 5:15 pm **Educational Session 9: Artificial Intelligence in the Clinic**
 Moderator: **Debra Patt**, Texas Oncology-Austin Central, Austin, Texas
 Patient Advocate: Kay Firth-Butterfield, Austin, Texas
- Hazards and Opportunities
Andrew Hantel, Dana-Faber Cancer Institute, Boston, Massachusetts
 - Beyond Chat GPT: Generative AI in Healthcare
Ian Maurer, Genomoncology , Cleveland, Ohio
 - Digital Tools for Clinical Practice
Emily Ray, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
 - **Panel Discussion**
- 3:30 – 5:15 pm **Educational Session 10: Immunotherapy**
 Moderator: **Heather McArthur**, UT Southwestern Medical Center, Dallas, Texas
- Immunotherapy in Early ER Positive Breast Cancer
Cesar Santa Maria, John Hopkins Medicine, Baltimore, Maryland
 - Optimization of Treatment in TNBC
Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands
 - The Future of Immunotherapy
Evanthia Roussos Torres, University of Southern California, Los Angeles, California
 - **Panel Discussion**
- 3:30 – 5:15 pm **Educational Session 11: Mind the Gap — Breast Cancer in Older Adults**
 Moderator to be announced
 Patient Advocate: Sandi Stanford, San Antonio, Texas
- The Aging Immune System with Hormonal Changes
Speaker to be announced
 - Defining and Avoiding Low Value Surgical Therapy
Christina Minami, Brigham and Women's Hospital, New York, New York
 - Systemic Therapies
Hans Wildiers, University Hospital Leuven, Leuven, Belgium
 - **Panel Discussion**

- 3:30 – 5:15 pm **Educational Session 12: The Biology and Treatment Implications of Organ Specific Metastases**
Moderator: **Heide Ford**, University of Colorado Denver School of Medicine, Denver, Colorado
Patient Advocate: Christine Hodgdon, Baltimore, Maryland
- Brain Metastases
Diana Cittelly, University of Colorado Anschutz Medical Campus, Aurora, Colorado
 - Liver Metastases
Peter Vermeulen, GZA Hospital Sint-Augustinus, Antwerp, Belgium
 - Bone Metastases
Rachelle Johnson, Vanderbilt University Medical Center, Nashville Tennessee
 - **Panel Discussion**
- 5:30 – 7:00 pm **Poster Session 4**
Halls 2-3
- 5:30 – 7:00 pm **Concurrent Poster Spotlight Sessions 16-18**
- 8:00 – 10:30 pm **SABCS Celebration**
Texas Ballroom, Grand Hyatt San Antonio Hotel

Friday, December 13 (all times are in CST)

- 7:00 – 8:30 am **Concurrent Poster Spotlight Sessions 11-15**
- 8:30 – 9:00 am **Plenary Lecture**
- Cell Atlases as Roadmaps in Cancer Immunology
Walid Khaled, University of Cambridge, Cambridge, United Kingdom
- 9:00 – 11:45 am **General Session 3**
- 12:00 – 12:50 pm **Rapid Fire 3**
- 12:30 -2:00 pm **Poster Session 5**
Halls 2-3
- 12:30 – 2:00 pm **The Pathologists Conundrum: IHC Testing in Breast Cancer**
Moderator: **David Rimm**, Yale School of Medicine, New Haven, Connecticut
- A Brief History of IHC in Breast Cancer and ASCO CAP Guidelines
Kim Allison, Stanford University/Stanford Cancer Institute, Palo Alto, California
 - The FDA’s Perspective: What is Required for a Companion Diagnostic Test
Reena Philips, FDA, Gaithersburg, Maryland
 - Evaluation of the accuracy of Reading IHC
Giuseppe Viale, European Institute of Oncology, Milan, Italy
 - Evaluation of the Accuracy of Digital Measuring
Andrew Beck, Path AI
- 12:30 – 1:45 pm **New Directions in Breast Cancer Prevention**
Moderator: **Gretchen Benson**, National Cancer Institute, Bethesda, Maryland
- Prevention Vaccines: Where Are We Now and Where Are We Going?
Olivera Finn, University of Pittsburgh, Pittsburgh, Pennsylvania
 - Can We Use Biomarkers to Implement Prevention?
Seema Khan, Feinberg School of Medicine of Northwestern University, Chicago, Illinois
 - From Bench to Clinical Trial: A New Target for Breast Cancer Prevention
Geoff Lindeman, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
 - **Panel Discussion**
- 2:00 – 2:50 pm **Debate: All Patients Should be Offered Universal Germline Genetic Testing**
Moderator: **Virginia Kaklamani**, UT Health San Antonio, San Antonio, Texas
- Opening Remarks and Polling
 - Debate For
Allison Kurian, Stanford University, Stanford, California
 - Debate Against
Raymond Kim, UHN Princess Margaret Cancer Centre, Toronto, Canada
 - Closing Remarks and Polling

3:00 – 5:00 pm

Year in Review

Moderators: **Carlos Arteaga**, UT Southwestern Medical Center, Dallas, Texas; and **Virginia Kaklamani**, UT Health San Antonio, San Antonio, Texas

- Translational Science Updates
Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York
- Early Breast Cancer Updates
Janice Tsang, University of Hong Kong, Hong Kong
- Advanced Breast Cancer Updates
Michael Danso, Virginia Oncology Associates, Norfolk, Virginia
Basic Science
- **Neil Vasan**, Columbia University, New York, New York

5:00 – 5:30 pm

Reception Break

5:30 – 7:00 pm

View from the Trenches

Moderator: **Joyce O’Shaughnessy**, UT Health San Antonio, San Antonio, Texas